Table 1.
Characteristics of included studies
| Study/year | Cancer type | Country/region | Study type | Included period | No of samples | Age | Primary outcome |
|---|---|---|---|---|---|---|---|
| Ugo De Giorgi (2019) | mRCC | Italy | P | 2015–2016 | 313 | 65 | OS/PFS |
| Cristian Lolli (2016) | mRCC | Italy | R | NA | 335 | 63 | OS/PFS |
| Wentao Zhang (2019) | BC | China | R | 2015–2019 | 209 | 66.7 | OS |
| Rebuzzi S.E. (2020) | mRCC | Italy | R | 2016–2019 | 189 | 69 | OS |
| Pawel Chrom (2018) | mRCC | Poland | R | 2008–2016 | 502 | NA | OS |
| Cristian Lolli (2016) | mCRPC | Italy | R | 2011–2015 | 230 | 74 | OS |
| Sacit Nuri Gorgel (2019) | MIBC | Turkey | R | 2006–2018 | 191 | 62.1 | OS/CSS |
| Ghanghoria A (2020) | RCC | India | R | NA | 33 | NA | OS |
| Hau-Chern Jan (2018) | UTUC | Taiwan | R | 2007–2017 | 424 | 70 | OS/PFS/CSS |
| Ya‑nan Man (2019) | mCRPC | China | R | 2010–2018 | 179 | 70 | OS |
| Emin Ozbek (2019) | RCC | Turkey | R | NA | 176 | 62 | OS/DSS |
| Liancheng Fan (2017) | mCRPC | China | R | 2013–2017 | 104 | 72 | OS/PFS |
| Palacka P (2017) | mUC | Slovakia | R | 2000–2015 | 185 | NA | OS/PFS |
| Sasanka Kumar Barua (2019) | mRCC | India | R | 2012–2017 | 31 | 60 | OS/PFS |
| Follow-up (months) | Cut-off | Cut-off selection | Treatment Methods | Stage/T stage | MVA | NOS score | Conference summary |
|---|---|---|---|---|---|---|---|
| 24 | 1375 | X-tile | Mix | T4 | Y | 7 | N |
| 49 | 730 | X-tile | No surgery | T4 | N | 7 | N |
| 1–48 | 507 | X-tile | Mix | Tis-T4 | Y | 6 | N |
| NA | 1375 | NA | No surgery | T4 | N | NA | Y |
| 52.5 | 730 | X-tile | Mix | T4 | Y | 8 | N |
| 1–30 | 535 | X-tile | No surgery | T4 | Y | 7 | N |
| 37 | 843 | ROC | Surgery | T2–T4 | Y | 8 | N |
| 6.8–38.6 | 8.67 | NA | Surgery | NA | N | NA | Y |
| 1–120 | 580 | ROC | Surgery | Ta–T4 | Y | 8 | N |
| 24 | 535 | NA | No surgery | T4 | Y | 7 | N |
| NA | 830/850 | ROC | Surgery | T1–T4 | N | 7 | N |
| 1–50 | 200 | ROC | No surgery | T4 | Y | 7 | N |
| 10 | NA | NA | No surgery | T4 | Y | NA | Y |
| NA | 883 | ROC | Surgery | T4 | Y | 6 | N |
mRCC: metastatic renal cell cancer; BC: bladder cancer; mCRPC: metastatic castration-resistant prostate cancer; MIBC: muscle invasive bladder cancer; RCC: renal cell cancer; UTUC: Upper-Tract Urothelial Carcinoma; mUC: metastatic urothelial carcinoma; P: prospective; R:retrospctive; OS: overall survival; PFS: progression-free survival; CSS: cancer-specific survival; DSS: disease-specific survival; MVA: multivariate analysis; NOS: Newcastle–Ottawa quality assessment scale; Y:yes; N: non